Related Experiment Video

Updated: Aug 21, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

3-hydroxy-3-methylglutaryl-CoA lyase deficiency in an adult with leukoencephalopathy

Felix Bischof1, Thomas Nägele, Ronald J A Wanders

  • 1Department of General Neurology, Hertie Institute for Clinical Brain Research, Tübingen, Germany. felix.bischof@uni-tuebingen.de

Annals of Neurology
|October 27, 2004
PubMed

Insights

3-Hydroxy-3-methylglutaryl-CoA lyase deficiency, a leucine metabolism disorder, can cause severe leukoencephalopathy in adults. Early diagnosis and L-carnitine treatment are crucial for managing this treatable condition.

Area of Science:

  • Biochemistry
  • Metabolic Disorders
  • Neuroscience

Background:

  • 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency is a rare inherited metabolic disorder affecting leucine breakdown.
  • Typically presents in early childhood with severe hypoglycemia and neurological complications.

Observation:

  • A 36-year-old woman presented with seizures, recurrent metabolic disturbances, and severe leukoencephalopathy.
  • Diagnosis involved amino acid analysis in urine and serum, confirmed by enzyme assay in fibroblasts.

Findings:

  • The patient demonstrated clinical improvement following oral L-carnitine supplementation.
  • This highlights L-carnitine's therapeutic potential in this specific metabolic disorder.

Implications:

  • 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency can manifest in adulthood, presenting as leukoencephalopathy.
  • Adult-onset cases may be underdiagnosed, necessitating consideration in differential diagnoses.
  • Early recognition and treatment with L-carnitine can prevent severe neurological sequelae.

More Related Videos

Selective Depletion of Microglia from Cerebellar Granule Cell Cultures Using L-leucine Methyl Ester08:10

Selective Depletion of Microglia from Cerebellar Granule Cell Cultures Using L-leucine Methyl Ester

Published on: July 7, 2015

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry06:53

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry

Published on: November 23, 2011

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...